CNO Closes the Bermuda Chapter and Turns Medicare's Wreckage Into a Sales Pitch
A third life-reserve treaty ends the deal cadence, a $56 million actuarial review flatters the quarter, and the sales streak finally cracked one tile — while the stock quietly re-rates.
CNO · Earnings Call · 2026-10-30
The treaty that ends the cadence
For three years CNO Financial has trained investors to expect roughly one Bermuda reinsurance treaty a year. On October 1 it signed the third — ceding about $270 million of U.S. statutory graded-benefit life reserves from Colonial Penn Life to its Bermuda affiliate — and then quietly shut the door behind it.
So with the closing of this third treaty, we've essentially completed the transactions that we had initially contemplated. We don't currently expect to see a material additional block of in-force reserves.
That is a genuine change in the story, not a rounding error. In July, Paul McDonough was still telling analysts “there are opportunities for us to seed more of our liabilities” — Paul Harrington McDonough, Chief Financial Officer · 2026-07-31 and that “a third treaty could be a part of that” — Paul Harrington McDonough, Chief Financial Officer · 2026-07-31. In November 2025 he sketched the natural endgame: “at some point, with our existing book other than new business will probably hit the right amount of in-force reserves that are ceded” — Paul McDonough, Chief Financial Officer · 2025-11-04. The endgame arrived faster than the cadence implied. Chief Actuary Jeremy Williams supplied the only detail that made the small headline reserve number feel large: “it is over 600,000 policies that are involved in the transaction” — Jeremy Williams, Chief Actuary · 2026-10-30.
What replaces deal-making is optimization: with annuity, health and now life liabilities sitting in one captive, the next phase is asset and capital mix work — "specific things that we're contemplating doing in 2027, all subject to regulatory approvals" — followed by a plain run-rate cadence in 2028. Note what has not happened: no dividend has been pulled out of Bermuda. The efficiency is captured at treaty settlement, not distribution. The Bermuda affiliate still ranks as the company's highest-momentum recurring theme and Treaty is one of this quarter's sharpest keyword gainers — but the trajectory has flipped from accumulating blocks to sweating them.
Medicare's wreckage is now the pitch
The growth engine is no longer framed as demographics. It is framed as disruption. Medicare Supplement NAP rose 41% in the quarter and has grown more than 60% over twelve months, total Medicare policies sold rose 20%, and management sized the opportunity in market terms: more than 3 million Medicare Advantage members need to choose new coverage for 2027 as carriers exit plans and pare benefits.
Gary Bhojwani's language has shifted accordingly. He used to sell the Medicare Advantage-versus-Supplement question as economically neutral — in February he said “economically, frankly, we're indifferent” — Gary Bhojwani, Chief Executive Officer · 2026-02-06. This quarter the argument is about advice:
“Any time there's a dislocation, that causes more consumers to want to seek advice, and that plays to our strength.” — Gary Bhojwani, Chief Executive Officer · 2026-10-30
The word dislocation is brand new to this company's lexicon and arrives with high momentum, alongside a re-energized Medicare Advantage to Medicare Supplement theme and the long-running absence of other credible alternatives refrain. It is a genuinely better articulation of the moat than "we sell both," and it is the crux of the local agent distribution model.
But there is a small crack in the indifference claim. Full-year fee income guidance is roughly $25 million, "primarily reflecting the continued shift from Medicare Advantage to Medicare Supplement." The mix shift is not free: CNO gives up distribution economics on MA to keep underwriting economics on MedSupp. "Indifferent" is a long-run ROE statement, not a near-term P&L one.
Where the earnings actually came from
Strip out noise and the quarter is still excellent: operating EPS of $1.42 excluding significant items, up 48%. But the headline $1.90 leans on a $56.3 million favorable annual actuarial review — broad-based across traditional life, fixed indexed annuities, supplemental health and long-term care, offset by worse Medicare Supplement claims — plus investment results where net investment income not allocated to products jumped 72%, running about $12 million above the long-term yield estimate that management explicitly says it does not expect to repeat. Two consecutive years of favorable unlocking is a pattern worth respecting, and equally worth discounting.
The cleaner signal is operating leverage. The expense ratio came in at 18.5% trailing twelve months, 50 basis points better year over year, and guidance was trimmed to 18.6%–18.8%. Analysts have now chased this line for three straight quarters — Ryan Krueger in May asked whether it was “all timing related in terms of the abnormally favorable expenses this quarter” — Ryan Krueger, Analyst · 2026-05-01; Joel Hurwitz asked again today and got the admission: “We have expected that it's a bit of timing and that it would come back. It hasn't through September” — Paul McDonough, Chief Financial Officer · 2026-10-30. An Expenses variance that survives three quarters of "it will normalize" is no longer timing — it is the compounding of total revenue against a cost base that is not growing with it.
Operating margin had already recovered to double digits through the June quarter, and operating income is at a cycle high. Free cash flow guidance of $220–$240 million is net of roughly $70 million of tech-modernization spend this year, with a comparable figure expected in 2027 — a genuine drag that management flags rather than hides.
The tape, and the streak that cracked
Price to operating income is 8.4x, up 36% year over year; price to earnings is 16.9x. The stock is +11.1% over 90 days in a single uninterrupted leg, no drawdown to speak of — a grind, not a squeeze. The fundamental justification is real: trailing operating ROE of 15.4% (14.1% ex-items) against a 12% target originally set for year-end 2027, which management now says is “clearly on track to exceed” — Paul McDonough, Chief Financial Officer · 2026-10-30, with new long-term targets promised for February. As Bhojwani framed it in May, “Twelve percent is nothing more than a waypoint.” — Gary Bhojwani, Chief Executive Officer · 2026-05-01
And yet: the 17th consecutive quarter of sales growth came with Life NAP down 9% (up 20% excluding a discontinued third-party pilot), and a fresh warning that D2C economic pressures will create "quarterly variability." This sits awkwardly against February's candor — “the pressure is definitely growing. The headwinds are definitely growing” — Gary Bhojwani, Chief Executive Officer · 2026-02-06 — now replaced by "we are not seeing anything that tells us there's going to be a material reduction in the need or demand for our services." Both can be true: need is inelastic, wallet share is not.
The tell for the next two quarters is whether the expense ratio and the actuarial tail can keep doing the work that the sales streak used to do alone.